Hoth Therapeutics, Inc. stock is down -2.86% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 5 February’s closed higher than January. 100% of analysts rate it a buy.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy. HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the. treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases. HT-003 to treat inflammatory bowel diseases, as well as acne and psor
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!